MAR 2 3 2001 UNI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):10Serial Number:0Filed:00For:H

 1647
 RECEIVED

 S. Turner
 APR 0 2 2001

 Gurney, Li, Pauley
 TECH CENTER 1600/2900

 09/328,877
 TECH CENTER 1600/2900

 06/09/99
 TECH CENTER 1600/2900

ENT/Docket No. 6142.N2 CP

Serial No. 09/328,877

Page 1

Human SEL-10 Polypeptides and Polynucleotides that Encode Them

Commissioner of Patents and Trademarks Washington, DC 20231 Sir:

This is in response to the office action mailed 26 September 2000 in the above-identified application, the shortened statutory period for response being until 26 October 2000. A request for a five month extension of time for response is included herewith to extend the period for response to 26 March 2001.

Election

Group II is provisionally elected with traverse.

Traversal of the Restriction Requirement

The applicant asserts that the embodiments of the invention in the proposed groups are so interrelated as to be capable of search together without undue burden. With regard to Groups I and II, it is well known in the art that the publicly available databases for searching protein and nucleic acid sequences give as their search results both nucleic acid and predicted amino acid sequences. It follows then, that both a nucleic acid (Group I) and protein sequence (Group II) may be searched without any considerable duplicity of effort.

The examination of the single claim of Group III could only be accomplished with reference to the SEL-10 polypeptides. In light of the fact that only one claim is involved, it seems that such a search would involve little additional effort.

With regard to Group IV, the applicant points out that the examiner apparently agrees that the subject matter of claim 22 i.e. a eukaryotic host cell propagating a vector expressing SEL-10, is capable of search with claims directed to SEL-10 encoding nucleic acid molecules. It is logical then, that the

subject matter of Group IV, cell lines expressing APP (in whatever manner) concomitantly with SEL-10, would pose no additional difficulty in searching.

The applicant agrees with the examiner that the material of Group IV are "related as product and process of use. The applicant respectfully points that the subject matter of Group IV is so inexorably linked to the subject matter of Groups I and II that it could be examined with little additional effort. If the nucleic acids and polypeptides of group I and II are found to be novel and nonobvious under 35 U.S.C § 103(a), the applicants may be entitled rejoinder of the claims to methods of using that product. *See* 1184 OG 86, (1996). The Applicants hereby request that, if the product claims of Group I or II are allowed the Patent Office rejoin the method claims of Group IV. To facilitate efficient examination, the Applicant's request that the claims of Group II and IV be examined simultaneously. The small number of claims in Group IV and their relatedness to Group II or Group I suggest that there will be no serious burden involved.

Compliance With the Sequence Rules

The Biotechnology System Branch has noted that the sequence listing as filed contains n's. Enclosed please find the substitute computer readable form and revised printed output of the sequence listings as requested in the Office Action of 9/26/00.

All sequence ambiguities have been noted in annotation section(s) < 220 > to < 223 >. The sequence reported has not changed from the original submission. Therefore the information recorded in computer readable form is identical to the written sequence listing as originally filed

Respectfully submitted,

States and states and

Edward F. Rehberg, Actorney Registration No. 34703

Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001

Telephone No. (616) 833-7829 or (616) 833-9500 Telefax No. (616) 833-8897 or (616) 833-2316

Date: _____

RECEIVED APR 0 2 2001 TECH CENTER 1600/2900

MAR 2 3 2 MAR 2 3 2	CERTIFICATE OF M Date of Deposit with M Date of Deposit with M CFR 1.8 on the date in	U.S. Postal Se his paper ¹ is b ndicated abov	eing deposited with	the United States Posta o the Commissioner of	al Service as first-clas	WUGAU 16 ² 1 No. 6142.N2 CP ECEIVED APR 0 2 2001 GENITER: 639/2900 marks,	, ť
	Washington, DC 202 Julie K. Lyon Name of Person Mail	<u>s, Legal A</u> ing Paper	Sig	rent and TRAD	EMARK OFFIC		#6 \$.q.) 4/7/w
	Art Unit	:	1647			Sh sequent	L
	Examiner	:	S. Turner				
	Applicant(s)	:	ME Gurney, AM	I Pauley, and J Li			
	Serial Number	:	09/328,877				
×	Filed	:	9 June <u>1</u> 999				
	For	:	Human Sel-10 P Them	Polypeptides and Po	lynucleotides that	Encode	

Commissioner of Patents and Trademarks Washington, DC 20231

TRANSMITTAL OF A RESPONSE TO A NON-FINAL ACTION (37 CFR 1.111)

Sir:


Transmitted herewith is a reply and/or amendment in the above-captioned application in response to the Examiner's action dated September 26, 2000.

6 04/09/2001 67K@MMEL 70000000 BY GTARI/of 93FACTI dment is being filed under 37 CFR 1.8 and the required Certificate 01 FC:128 1890 for the ling appears above.

- VI FUIIC
- [] An additional fee in the amount of \$ is required for the amended claims presented and has been calculated as shown in the attached sheet.

Please charge Deposit Account No. <u>21-0718</u> in the amount of the additional fee above on such greater or lesser amount of excess fees for claims as the Commissioner determines is required by law. Triplicate copies of this sheet are enclosed.

EXTENSION OF TIME. In the event this paper is not filed prior to the time set for response, applicant(s) hereby petition for an extension of the period for filing the attached reply and amendment to the date of filing this paper, and hereby authorize the Commissioner to charge the extension fee as may be required by 37 CFR 1.17, to Deposit Account No. <u>21-0718</u>. If for any



reason the extension requested above is insufficient to extend this period to the date of this paper, applicant(s) hereby petition for the revival of the above-captioned application as having been unintentionally abandoned and authorize the Commissioner to charge the required fees under 37 CFR 1.17 to Deposit Account No. <u>21-0718</u>.

Respectfully submitted,

J

١,

Edward F. Rehberg, Attorney Registration No. 34,703

Date: _____arch 20, 2001

Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001

Telephone No. (616) 833-7829 or (616) 833-9500 Telefax No. (616) 833-8897 or (616) 833-2316

Enclosures:

Reply/Amendment [] Calculation of Additional Fees for Amended Claims [X] Sequence listing in paper and computer readable form